Shorted
Tryptamine logo
TYP

Tryptamine

Short interest
0.00%
0.00 pp 30d
as of 20 Nov 2025
Reported shorts
6
Shares on issue
1.560B

Tryptamine (TYP) company profile

Profile, insiders and operations

Company

AI-generated research profile of Tryptamine

Biotechnology
Pharmaceuticals
Drug Development
ASX
Research

Tryptamine (TYP) is an ASX-listed company focused on the research and development of novel therapeutic compounds. The company aims to address unmet medical needs through innovative drug discovery and clinical trials. Further details regarding their specific market position and unique value proposition are unavailable without additional information.

Director trades

20 trades recorded

DateDirectorTypeSharesPriceValue
2026-08-07Herwig Janssen
buy
766,871$0.033$25,000
2026-05-14Unknown Director
buy
---
2026-05-12Jason Carroll
buy
1,288,236$0.035$45,626
2026-04-20CN, DT, JC & HJ
buy
---
2026-04-14Chris Ntoumenopoulos
buy
7,941,176$0.034$270,000
2026-03-10Unknown Director
buy
---
2026-03-06Jason Carroll
buy
2,500,000$0.030$75,000
2026-02-06Jason Carroll
buy
1,000,000$0.030$30,000
2026-02-06Unknown Director
buy
---
2026-02-04Unknown Director
buy
---
2026-02-03Jason Carroll
buy
1,000,000$0.030$30,000
2026-01-16Herwig Janssen
other
1,931,012$0.033$64,109.59
2026-01-16Unknown Director
buy
---
2025-12-19Chris Ntoumenopoulos
exercise options
20,000,000--
2025-12-19CN, DT, GJ, HJ & JC
buy
---
2025-03-31Jason Carroll
other
22,500,000$0.013$300,000
2025-03-31Chris Ntoumenopoulos
other
15,000,000$0.013$200,000
2025-03-31Daniel Tillett
other
87,250,000$0.011$1,000,000
2025-03-31Unknown Director
buy
---
2025-03-31Unknown Director
buy
---

TYP intelligence dossier

Public-source evidence for this company, with industry drill-up links.

  • Tax paid and taxable income records
  • Government contracts and public money
  • Emissions and trade exposure
  • Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required